HopeStage
Back to all studies
CompletedNCT05179525

Comparing two risperidone formulations for schizophrenia care

About this titleRead the official source — NCT05179525
Medication studyAges 18–65United States
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 65 years.

Listed locations
Garden Grove and 3 more locationsSee all locations and recruitment
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: March 9, 2021
Recruitment status
Completed
Enrollment listed in the registry
80
Sponsor
Rovi Pharmaceuticals Laboratories
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Drug
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT05179525
Official title
Show the full official title

An Open-Label, One-Sequence Study to Evaluate the Steady- State Comparative Bioavailability of Intramuscular Risperidone ISM® and EU Risperdal® (Sourced From Germany)

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Garden Grove · Gaithersburg · Berlin

1 more locations
  • DeSoto

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Rovi Pharmaceuticals Laboratories, a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including Risperidone ISM® 100 mg and Risperdal 4mg Tablet.

Who was this study for?

Listed age limits: 18 years to 65 years.

Want to explore more studies?

Explore studies